Is CLRB or BTMD more profitable?

biote has a net margin of 8.29% compared to Cellectar Biosciences' net margin of 0.00%. biote's return on equity of -25.72% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -349.24% -153.18% biote 8.29% -25.72% 15.12%

Which has stronger earnings and valuation, GANX or CLRB?

Gain Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gain Therapeutics N/A N/A -$20.16M -$0.58 N/A Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A

Is GANX or CLRB more profitable?

Gain Therapeutics' return on equity of -201.44% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -201.44% -136.24% Cellectar Biosciences N/A -349.24% -153.18%

Does the media favor GANX or CLRB?

In the previous week, Cellectar Biosciences had 1 more articles in the media than Gain Therapeutics. MarketBeat recorded 2 mentions for Cellectar Biosciences and 1 mentions for Gain Therapeutics. Cellectar Biosciences' average media sentiment score of 0.37 beat Gain Therapeutics' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, LONA or CLRB?

Athira Pharma is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$105.61M -$5.21 N/A Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A

Is LONA or CLRB more profitable?

Cellectar Biosciences' return on equity of -349.24% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -381.01% -225.74% Cellectar Biosciences N/A -349.24% -153.18%

Does the media refer more to LONA or CLRB?

In the previous week, Athira Pharma and Athira Pharma both had 2 articles in the media. Cellectar Biosciences' average media sentiment score of 0.37 beat Athira Pharma's score of 0.34 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athira Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cellectar Biosciences (CLRB) Competitors

$2.49 -0.01 (-0.40%)

Closing price 04:00 PM Eastern

Extended Trading

$2.50 +0.01 (+0.40%)

As of 06:50 PM Eastern

Compare

CLRB vs. BTMD, HRTX, LFVN, GANX, and LONA

Should you buy Cellectar Biosciences stock or one of its competitors? MarketBeat compares Cellectar Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cellectar Biosciences include biote (BTMD), Heron Therapeutics (HRTX), Lifevantage (LFVN), Gain Therapeutics (GANX), and Athira Pharma (LONA). These companies are all part of the "pharmaceutical products" industry.

How does Cellectar Biosciences compare to biote?

Cellectar Biosciences (NASDAQ:CLRB) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 2.6% of Cellectar Biosciences shares are held by company insiders. Comparatively, 32.4% of biote shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cellectar Biosciences has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, biote has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market.

biote has a net margin of 8.29% compared to Cellectar Biosciences' net margin of 0.00%. biote's return on equity of -25.72% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
biote	8.29%	-25.72%	15.12%

In the previous week, Cellectar Biosciences had 2 more articles in the media than biote. MarketBeat recorded 2 mentions for Cellectar Biosciences and 0 mentions for biote. Cellectar Biosciences' average media sentiment score of 0.37 beat biote's score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectar Biosciences	Neutral
biote	Neutral

Cellectar Biosciences currently has a consensus target price of $11.00, suggesting a potential upside of 341.77%. biote has a consensus target price of $2.75, suggesting a potential upside of 30.95%. Given Cellectar Biosciences' higher probable upside, equities research analysts plainly believe Cellectar Biosciences is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

biote has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
biote	$188.16M	0.42	$27.05M	$0.44	4.77

Summary

biote beats Cellectar Biosciences on 11 of the 15 factors compared between the two stocks.

How does Cellectar Biosciences compare to Heron Therapeutics?

Cellectar Biosciences (NASDAQ:CLRB) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Heron Therapeutics has higher revenue and earnings than Cellectar Biosciences. Heron Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Heron Therapeutics	$150.71M	0.55	-$20.19M	-$0.18	N/A

In the previous week, Cellectar Biosciences had 2 more articles in the media than Heron Therapeutics. MarketBeat recorded 2 mentions for Cellectar Biosciences and 0 mentions for Heron Therapeutics. Cellectar Biosciences' average media sentiment score of 0.37 beat Heron Therapeutics' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectar Biosciences	Neutral
Heron Therapeutics	Neutral

16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 2.6% of Cellectar Biosciences shares are held by insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cellectar Biosciences has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

Cellectar Biosciences currently has a consensus target price of $11.00, indicating a potential upside of 341.77%. Heron Therapeutics has a consensus target price of $2.50, indicating a potential upside of 474.71%. Given Heron Therapeutics' higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cellectar Biosciences has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. Cellectar Biosciences' return on equity of -349.24% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

Summary

Heron Therapeutics beats Cellectar Biosciences on 8 of the 15 factors compared between the two stocks.

How does Cellectar Biosciences compare to Lifevantage?

Cellectar Biosciences (NASDAQ:CLRB) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Lifevantage has a net margin of 2.94% compared to Cellectar Biosciences' net margin of 0.00%. Lifevantage's return on equity of 23.89% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Lifevantage	2.94%	23.89%	12.47%

In the previous week, Cellectar Biosciences had 2 more articles in the media than Lifevantage. MarketBeat recorded 2 mentions for Cellectar Biosciences and 0 mentions for Lifevantage. Cellectar Biosciences' average media sentiment score of 0.37 beat Lifevantage's score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectar Biosciences	Neutral
Lifevantage	Neutral

Cellectar Biosciences has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Lifevantage has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

Lifevantage has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Lifevantage	$228.53M	0.34	$9.81M	$0.45	13.84

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 35.3% of Lifevantage shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by company insiders. Comparatively, 22.0% of Lifevantage shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cellectar Biosciences currently has a consensus price target of $11.00, suggesting a potential upside of 341.77%. Lifevantage has a consensus price target of $5.00, suggesting a potential downside of 19.74%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lifevantage beats Cellectar Biosciences on 10 of the 15 factors compared between the two stocks.

How does Cellectar Biosciences compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Gain Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 388.51%. Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 341.77%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Gain Therapeutics is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Gain Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	N/A	N/A	-$20.16M	-$0.58	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

Gain Therapeutics' return on equity of -201.44% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Cellectar Biosciences	N/A	-349.24%	-153.18%

In the previous week, Cellectar Biosciences had 1 more articles in the media than Gain Therapeutics. MarketBeat recorded 2 mentions for Cellectar Biosciences and 1 mentions for Gain Therapeutics. Cellectar Biosciences' average media sentiment score of 0.37 beat Gain Therapeutics' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gain Therapeutics has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

Summary

Gain Therapeutics beats Cellectar Biosciences on 8 of the 13 factors compared between the two stocks.

How does Cellectar Biosciences compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Cellectar Biosciences' return on equity of -349.24% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Athira Pharma is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

Athira Pharma has a beta of 1.97, meaning that its stock price is 97% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

In the previous week, Athira Pharma and Athira Pharma both had 2 articles in the media. Cellectar Biosciences' average media sentiment score of 0.37 beat Athira Pharma's score of 0.34 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Athira Pharma currently has a consensus target price of $15.00, indicating a potential upside of 74.62%. Cellectar Biosciences has a consensus target price of $11.00, indicating a potential upside of 341.77%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Cellectar Biosciences beats Athira Pharma on 7 of the 11 factors compared between the two stocks.

Get Cellectar Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLRB vs. The Competition

Export

Metric	Cellectar Biosciences	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$19.90M	$8.18B	$6.56B	$12.24B
Dividend Yield	N/A	2.59%	2.69%	5.82%
P/E Ratio	-0.37	15.21	25.17	23.98
Price / Sales	N/A	5.89	553.76	120.62
Price / Cash	N/A	16.83	44.82	54.51
Price / Book	1.32	3.29	10.76	6.41
Net Income	-$21.79M	$226.25M	$3.56B	$337.14M
7 Day Performance	0.40%	-0.96%	1.37%	-0.48%
1 Month Performance	-22.19%	-2.77%	0.81%	0.49%
1 Year Performance	-74.33%	0.16%	30.53%	28.16%

Cellectar Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLRB Cellectar Biosciences	4.1877 of 5 stars	$2.49 -0.4%	$11.00 +341.8%	-72.0%	$19.90M	N/A	N/A	10
BTMD biote	4.2607 of 5 stars	$2.18 -3.3%	$2.75 +26.4%	-46.4%	$81.77M	$192.22M	4.95	194
HRTX Heron Therapeutics	1.4143 of 5 stars	$0.43 -0.1%	$2.50 +483.8%	-80.2%	$81.05M	$154.90M	N/A	300
LFVN Lifevantage	1.9957 of 5 stars	$6.35 +4.4%	$5.00 -21.3%	-48.8%	$80.14M	$228.53M	14.11	260
GANX Gain Therapeutics	1.9598 of 5 stars	$1.82 -1.6%	$8.50 +367.0%	+4.7%	$77.62M	$50K	N/A	20	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLRB) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cellectar Biosciences (CLRB) Competitors

CLRB vs. BTMD, HRTX, LFVN, GANX, and LONA

How does Cellectar Biosciences compare to biote?

Summary

How does Cellectar Biosciences compare to Heron Therapeutics?

Summary

How does Cellectar Biosciences compare to Lifevantage?

Summary

How does Cellectar Biosciences compare to Gain Therapeutics?

Summary

How does Cellectar Biosciences compare to Athira Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB vs. The Competition

Cellectar Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cellectar Biosciences (CLRB) Competitors

CLRB vs. BTMD, HRTX, LFVN, GANX, and LONA

How does Cellectar Biosciences compare to biote?

Do insiders & institutionals hold more shares of CLRB or BTMD?

Which has more volatility and risk, CLRB or BTMD?

Is CLRB or BTMD more profitable?

Does the media favor CLRB or BTMD?

Do analysts prefer CLRB or BTMD?

Which has better earnings and valuation, CLRB or BTMD?

Summary

How does Cellectar Biosciences compare to Heron Therapeutics?

Which has preferable valuation and earnings, CLRB or HRTX?

Does the media favor CLRB or HRTX?

Do institutionals and insiders have more ownership in CLRB or HRTX?

Which has more volatility & risk, CLRB or HRTX?

Do analysts prefer CLRB or HRTX?

Is CLRB or HRTX more profitable?

Summary

How does Cellectar Biosciences compare to Lifevantage?

Is CLRB or LFVN more profitable?

Does the media refer more to CLRB or LFVN?

Which has more volatility & risk, CLRB or LFVN?

Which has higher valuation & earnings, CLRB or LFVN?

Do insiders & institutionals hold more shares of CLRB or LFVN?

Do analysts recommend CLRB or LFVN?

Summary

How does Cellectar Biosciences compare to Gain Therapeutics?

Do insiders & institutionals hold more shares of GANX or CLRB?

Do analysts prefer GANX or CLRB?

Which has stronger earnings and valuation, GANX or CLRB?

Is GANX or CLRB more profitable?

Does the media favor GANX or CLRB?

Which has more volatility & risk, GANX or CLRB?

Summary

How does Cellectar Biosciences compare to Athira Pharma?

Is LONA or CLRB more profitable?

Which has better earnings & valuation, LONA or CLRB?

Which has more risk and volatility, LONA or CLRB?

Does the media refer more to LONA or CLRB?

Do analysts recommend LONA or CLRB?

Do insiders & institutionals have more ownership in LONA or CLRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB vs. The Competition

Cellectar Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools